Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 339

recruiting
3 967
countries
28
conditions
2 124

10 514 trials match your criteria

Colitis ulcerative+1

Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab

Type 2 diabetes mellitus

Not yet recruiting

Effect of Adding Dasatinib to Semaglutide on Metabolic Health in Adults with Uncontrolled Type 2 Diabetes

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Dasatinib

Type 2 diabetes mellitus

Not yet recruiting

Phase 3 Study of Maridebart Cafraglutide versus Semaglutide as Add‑on to Metformin (± SGLT‑2 Inhibitor) in Adults with Type 2 Diabetes Not Controlled by Metformin

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide

Endometrial cancer

Not yet recruiting

Maintenance Treatment Study of gsk5733584 with dostarlimab or pembrolizumab in patients with mismatch repair proficient advanced or recurrent endometrial cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab

Study of combination therapy with an endothelin receptor antagonist, phosphodiesterase‑5 inhibitor, and sotatercept in newly diagnosed pulmonary arterial hypertension

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept

Miglustat oral solution safety and efficacy study in pediatric patients with CLN3 disease

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Miglustat

Bladder cancer

Not yet recruiting

Phase II study of [68Ga]BED003 PET imaging and liquid biopsy for staging bladder cancer in bladder cancer patients

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:GA68-ONCOFAP

Intellectual disability

Not yet recruiting

Safety and Tolerability of Intrathecal CMP-002 in Participants with SYNGAP1-Related Disorder

Investigational
Countries:FranceFrance
  • Participants:0–17 years
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years

Myelodysplastic syndrome

Not yet recruiting

Study of Bexmarilimab with Azacitidine versus Placebo with Azacitidine in Treatment‑Naïve Higher‑Risk Myelodysplastic Syndrome Patients

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bexmarilimab

COVID-19+1

Not yet recruiting

Safety and immune response of investigational mRNA vaccine GSKVX000000078664 versus drug combination in adults with flu and COVID-19

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Elasomeran

Adenocarcinoma pancreas

Not yet recruiting

Low‑dose cyclophosphamide maintenance therapy to prevent recurrence in patients with pancreatic cancer after surgery and neoadjuvant chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Cyclophosphamide Monohydrate
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.